Sellas Life Sciences Group Inc (SLS)
R&D Expense Growth
22.29%
Quarterly · Period ending:
SLS R&D Expense Growth
Latest reported22.29%period ending
Latest reported22.29%period ending
SLS Quarterly R&D Growth (QoQ) (0.00% → 22.29%)
Latest values, visible window
High-resolution chart · PNG
SLS r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 22.285% | |
| 8.4355% | |
| 12.1917% | |
| 8.9124% | |
| 20.78% | |
| -27.7665% | |
| 1.7194% | |
| -15.8889% | |
| 1.4674% | |
| 0.2747% | |
| -12.3172% | |
| -1.8572% | |
| -17.438% | |
| 22.7164% | |
| 36.525% | |
| -22.5538% | |
| 19.9089% | |
| 35.8974% | |
| -25.2808% | |
| 31.3947% | |
| -19.3277% | |
| 54.6012% | |
| 17.068% | |
| 3.8158% | |
| 22.3176% | |
| -63.2999% | |
| 182.3235% | |
| 30.2679% | |
| -25.7127% | |
| -85.9177% | |
| 667.5% | |
| 8.0402% | |
| -11.7517% | |
| 154.0845% | |
| -25.3417% | |
| -53.4736% | |
| -13.4632% | |
| -48.8523% | |
| 27.4283% | |
| -41.3117% | |
| 13.4485% | |
| 16.5275% | |
| -18.6237% | |
| -20.2445% | |
| 23.5536% | |
| -7.1269% | |
| -10.7189% | |
| -12.9384% | |
| 19.1876% | |
| -4.4595% | |
| 95.0454% | |
| -31.141% | |
| 3.8378% | |
| 25.117% | |
| -2.5905% | |
| 12.0699% | |
| 9.6698% | |
| -8.3986% | |
| 170.8851% | |
| -48.859% | |
| 23.9796% | |
| 23.4116% | |
| -9.7624% | |
| 30.4582% | |
| -22.9491% | |
| -18.3552% | |
| 12.8168% | |
| 15.0798% | |
| 28.3192% | |
| -35.5485% | |
| 96.8638% | |
| -59.6529% | |
| 154.2279% | |
| -70.4187% | |
| 259.5308% | |
| -72.8647% | |
| 357.5243% | |
| 1,816.6667% | |
| 0% |